Etienne Morel, collaborator of ENYO Pharma, gave a talk describing the results of our collaboration entitled “From virus-host molecular crosstalk to ER-mitochondria membrane interface mobilization in innate immunity” at the Virology Virtual Conference on March the 23th :
New publication : Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy
Together with the team of Etienne Morel, ENYO Pharma continues the antiviral exploration of its molecule targeting the NEET proteins, in the context of influenza virus. In this new article, we demonstrate that MITO-C exerts a membrane signature that strictly counteracts the signature applied by influenza virus infection on the mitochondria and on endoplasmic reticulum-mitochondria contact sites. Consequently, MITO-C potentiates Interferon expression and inhibits viral replication. Publication here
ENYO Pharma has been selected to take part in the French Tech 120 #FT120 program for the second consecutive year. We will thus benefit from specific guidance and visibility. Created by the French government, this program offers support to French scaleups with the potential to become global technology leaders.
ENYO is proud to share international collaborative study showing the development of MITO-C (one compound of EYP002 series) a new class of molecule targeting the
NEET family of protein. This work co-led by Etienne Morel (INEM, Paris, France) and Benoît de Chassey (ENYO Pharma, Lyon France) and sponsored by ENYO Pharma nicely shows that MITO-C (one compound of EYP002 series) modulates mitochondria morphogenesis and stabilizes ER-Mitochondria contact sites. This seminal fundamental results opens potential indications that go beyond infectious diseases e.g.
We are pleased to announce that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) vonafexor for our FXR agonist lead candidate previously referred to as EYP001.